Daily Aspirin: Not a Reliable Way to Prevent Bowel Cancer & Raises Bleeding Risk

Millions of people worldwide take daily aspirin, some with the hope of preventing colorectal cancer. However, a major review published by Cochrane, a globally recognized organization dedicated to systematic reviews of healthcare interventions, suggests that for most individuals, this practice isn’t a reliable preventative measure and carries immediate risks. The analysis underscores the importance of carefully weighing potential benefits against the well-established danger of bleeding associated with regular aspirin use.

Understanding Colorectal Cancer and Aspirin’s Role

Colorectal cancer, encompassing both colon and rectal cancers, is a significant global health concern. Prevention strategies typically center on lifestyle factors – diet, exercise, and regular screening tests like colonoscopies – and, increasingly, investigation into the potential role of common medications. Nonsteroidal anti-inflammatory drugs (NSAIDs), including aspirin and ibuprofen, have been studied for their possible cancer-preventative effects. NSAIDs are frequently used to manage pain, inflammation, and fever, but whether they can proactively reduce the risk of colorectal cancer has been a subject of ongoing debate.

Researchers at West China Hospital of Sichuan University in China undertook a comprehensive review of 10 randomized controlled trials, encompassing a substantial 124,837 participants. Their goal was to determine if aspirin or other NSAIDs could lower the risk of colorectal cancer or its precursor, adenomas (precancerous growths), in individuals considered to be at average risk. Crucially, the review found insufficient evidence to support a benefit from non-aspirin NSAIDs, meaning the findings primarily pertain to aspirin.

Limited Evidence of Benefit, Immediate Bleeding Risk

The review’s findings indicate that aspirin is unlikely to reduce the risk of developing bowel cancer within the first 5 to 15 years of consistent use. Whereas some studies hinted at a possible protective effect after longer periods – exceeding 10 to 15 years – the researchers expressed low confidence in this evidence. This is as these longer-term observations were made *after* the original trials had concluded. During this follow-up period, participants’ aspirin use may have changed, introducing potential biases and making it challenging to isolate the drug’s true effect.

“While the idea of aspirin preventing bowel cancer in the long run is intriguing, our analysis shows that this benefit is not guaranteed and comes with immediate risks,” explains Dr. Zhaolun Cai, the lead author of the review. ScienceDaily reports on the study’s findings.

Perhaps more concerning, the researchers found robust evidence that daily aspirin use significantly increases the risk of serious extracranial hemorrhage (bleeding outside the brain) and likely elevates the risk of hemorrhagic stroke. Even low-dose aspirin, often referred to as “baby aspirin,” can increase the likelihood of bleeding. This risk is particularly pronounced in older adults and individuals with pre-existing conditions like ulcers or bleeding disorders.

Dr. Bo Zhang, a senior author on the study, emphasizes the timing of these risks: “My biggest worry is that people might assume that taking an aspirin today will protect them from cancer tomorrow. In reality, any potential preventive effect takes over a decade to appear, if it appears at all, while the bleeding risk begins immediately.”

Not a Universal Solution: Considering Individual Risk

It’s important to note that previous research has suggested aspirin may be beneficial for specific high-risk groups, such as individuals with Lynch syndrome, an inherited condition that significantly increases the risk of colorectal cancer. However, this Cochrane review specifically focused on individuals at average risk, and for this population, the evidence for long-term benefit remained highly uncertain.

The authors strongly advise against initiating aspirin therapy for cancer prevention without a thorough discussion with a healthcare professional to assess individual bleeding risks. The Baltimore Sun covers the implications of the review for everyday patients.

“This review reinforces that we must move away from a one-size-fits-all approach,” says Dr. Dan Cao, another senior author. “Widespread aspirin use in the general population simply isn’t supported by the evidence. The future lies in precision prevention — using molecular markers and individual risk profiles to identify who might benefit most and who is most at risk.”

The Complex Balance of Benefits and Harms

The researchers conclude that aspirin’s role in cancer prevention is far more nuanced than previously thought. The balance between potential benefits and established harms can change over time, making a simple recommendation difficult. As Dr. Zhang states, “As scientists, we must follow the evidence where it leads. Our rigorous analysis of the highest-quality trials reveals that the ‘aspirin for cancer prevention’ story is more complex than a simple ‘yes or no.’ The current evidence does not support a blanket recommendation for aspirin use purely to prevent bowel cancer.”

This isn’t to say aspirin has no place in healthcare. It remains a valuable medication for preventing cardiovascular events, such as heart attacks and strokes, in certain individuals. However, the decision to use aspirin should always be made in consultation with a doctor, carefully considering the individual’s overall health profile and risk factors. Cochrane provides further information on their methodology, and findings.

What Comes Next: Refining Prevention Strategies

The findings from this Cochrane review will likely prompt further research into more targeted approaches to colorectal cancer prevention. This includes exploring the use of biomarkers – measurable indicators of biological states – to identify individuals who might genuinely benefit from aspirin therapy while minimizing risks. Ongoing surveillance efforts will continue to monitor the long-term effects of aspirin use in various populations, providing a more comprehensive understanding of its potential benefits and harms. Public health guidance will be updated as new evidence emerges, ensuring that recommendations are based on the most current and reliable information.